These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31397948)

  • 1. Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer-Lipid Amphiphile Conjugates of Small-Molecule TLR7/8 Agonists.
    De Vrieze J; Louage B; Deswarte K; Zhong Z; De Coen R; Van Herck S; Nuhn L; Kaas Frich C; Zelikin AN; Lienenklaus S; Sanders NN; Lambrecht BN; David SA; De Geest BG
    Angew Chem Int Ed Engl; 2019 Oct; 58(43):15390-15395. PubMed ID: 31397948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles-TLR7/8 Agonist Conjugates.
    Van Herck S; Deswarte K; Nuhn L; Zhong Z; Portela Catani JP; Li Y; Sanders NN; Lienenklaus S; De Koker S; Lambrecht BN; David SA; De Geest BG
    J Am Chem Soc; 2018 Oct; 140(43):14300-14307. PubMed ID: 30277761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.
    Wang B; Van Herck S; Chen Y; Bai X; Zhong Z; Deswarte K; Lambrecht BN; Sanders NN; Lienenklaus S; Scheeren HW; David SA; Kiessling F; Lammers T; De Geest BG; Shi Y
    J Am Chem Soc; 2020 Jul; 142(28):12133-12139. PubMed ID: 32524819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.
    Nuhn L; Van Hoecke L; Deswarte K; Schepens B; Li Y; Lambrecht BN; De Koker S; David SA; Saelens X; De Geest BG
    Biomaterials; 2018 Sep; 178():643-651. PubMed ID: 29573820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
    Jangra S; De Vrieze J; Choi A; Rathnasinghe R; Laghlali G; Uvyn A; Van Herck S; Nuhn L; Deswarte K; Zhong Z; Sanders NN; Lienenklaus S; David SA; Strohmeier S; Amanat F; Krammer F; Hammad H; Lambrecht BN; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9467-9473. PubMed ID: 33464672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.
    Nuhn L; Vanparijs N; De Beuckelaer A; Lybaert L; Verstraete G; Deswarte K; Lienenklaus S; Shukla NM; Salyer AC; Lambrecht BN; Grooten J; David SA; De Koker S; De Geest BG
    Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8098-103. PubMed ID: 27382168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
    Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
    Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic Acid Conjugates of TLR7/8 Agonists for Targeted Delivery to Secondary Lymphoid Tissue.
    Yoo E; Salyer ACD; Brush MJH; Li Y; Trautman KL; Shukla NM; De Beuckelaer A; Lienenklaus S; Deswarte K; Lambrecht BN; De Geest BG; David SA
    Bioconjug Chem; 2018 Aug; 29(8):2741-2754. PubMed ID: 29969553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
    Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CO-DELIVERY of glutamic acid-extended peptide antigen and imidazoquinoline TLR7/8 agonist via ionizable lipid nanoparticles induces protective anti-tumor immunity.
    Ye T; Zhong Z; Cappellesso F; Deswarte K; Chen Y; Lauwers H; De Lombaerde E; Gontsarik M; Lienenklaus S; Van Lysebetten D; Sanders NN; Lambrecht BN; De Koker S; Laoui D; De Geest BG
    Biomaterials; 2024 Dec; 311():122693. PubMed ID: 38996672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
    Butchar JP; Mehta P; Justiniano SE; Guenterberg KD; Kondadasula SV; Mo X; Chemudupati M; Kanneganti TD; Amer A; Muthusamy N; Jarjoura D; Marsh CB; Carson WE; Byrd JC; Tridandapani S
    Clin Cancer Res; 2010 Apr; 16(7):2065-75. PubMed ID: 20332325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
    Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
    Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.
    Shukla NM; Kimbrell MR; Malladi SS; David SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2211-4. PubMed ID: 19285861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering Strategies for Lymph Node Targeted Immune Activation.
    Chen Y; De Koker S; De Geest BG
    Acc Chem Res; 2020 Oct; 53(10):2055-2067. PubMed ID: 32910636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
    Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
    Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.
    Gadd AJ; Greco F; Cobb AJ; Edwards AD
    Bioconjug Chem; 2015 Aug; 26(8):1743-52. PubMed ID: 26133029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
    Yang M; Larson PG; Brown L; Schultz JR; Kucaba TA; Griffith TS; Ferguson DM
    Bioorg Med Chem Lett; 2022 Mar; 59():128548. PubMed ID: 35051578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of innate immune cells by light-activated TLR7/8 agonists.
    Ryu KA; Stutts L; Tom JK; Mancini RJ; Esser-Kahn AP
    J Am Chem Soc; 2014 Aug; 136(31):10823-5. PubMed ID: 25029205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
    Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
    J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.